Treatment of latent Tuberculosis infection in HIV infected persons

Added August 13, 2019

Citation: Akolo C., Adetifa I., Shepperd S., et al. Treatment of latent Tuberculosis infection in HIV infected persons. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD00171. DOI: 10.1002/14651858.CD00171.pub3

Currently available trials do not provide sufficient data to draw firm conclusions about the value of preventive therapy for improving survival in persons infected with HIV.

Most people infected with tuberculosis (TB) never get TB symptoms. This is called latent TB. People infected with HIV/AIDS are at increased risk of getting TB and about 30% of people with HIV who have latent TB will eventually get active TB. Treatment of latent tuberculosis infection helps to prevent progression to active disease in HIV-negative populations, but the extent and magnitude of protection associated with preventive therapy in those infected with HIV needs quantifying. The review evaluated 10 trials  that were included in the original systematic review (Woldehanna 2004), and two new trials that met the inclusion criteria. The update now includes 12 trials with a total of 8578 randomized participants. Authors found that the risk of developing active TB was reduced when people infected with both HIV and TB used isoniazid. Isoniazid for latent TB is usually taken for six to 12 months, but more research is still needed to show optimal duration of treatment, the best treatment regime for people with HIV, and especially the best regimen in combination with HIV drugs.


Disclaimer: This summary has been written by staff and volunteers of Evidence Aid in order to make the content of the original document accessible to decision makers who are searching for the available evidence on the health of refugees and asylum seekers but may not have the time, initially, to read the original report in full. This summary is not intended as a substitute for the medical advice of physicians, other health workers, professional associations, guideline developers, or national governments and international agencies. If readers of this summary think that the evidence that is presented within it is relevant to their decision-making they should refer to the content and details of the original article, and the advice and guidelines offered by other sources of expertise, before making decisions. Evidence Aid cannot be held responsible for any decisions made about the health of refugees and asylum seekers on the basis of this summary alone.